Trial Profile

Double-blind, Placebo Controlled, First in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of YCT-529

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YCT 529 (Primary)
Indications Pregnancy
Focus Adverse reactions; First in man
Sponsors YourChoice Therapeutics

Most Recent Events

22 Jul 2025 Results published in the Media Release
22 Jul 2025 According to a YourChoice Therapeutics media release, the company announced that Communications Medicine, a Nature Portfolio Journal, published the results of YCT-529's first-in-human study.
03 Jun 2024 Status changed from recruiting to completed, according to a YourChoice Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com